Shattuck Labs prices $75 million public offering at $4 per share

Shattuck Labs Inc. (NASDAQ: STTK) announced the pricing of its public offering at $4 per share, expecting to raise approximately $75 million in gross proceeds before fees and expenses.

The biotechnology company will sell 10,879,376 shares of common stock and offer pre-funded warrants to purchase up to 7,870,624 shares at $3.9999 per warrant to certain investors. The pre-funded warrants carry an exercise price of $0.0001 per share and are immediately exercisable.

The offering is scheduled to close on June 11, 2026, subject to customary closing conditions. Shattuck has granted underwriters a 30-day option to purchase up to an additional 2,812,500 shares at the public offering price, minus underwriting discounts and commissions.

Leerink Partners, J.P. Morgan, Piper Sandler and Cantor serve as joint bookrunning managers for the offering. The Securities and Exchange Commission declared the related registration statement effective on January 21, 2026.

Austin, Texas and Durham, North Carolina-based Shattuck develops monoclonal and bispecific DR3 blocking antibodies for inflammatory and immune-mediated diseases. The company's lead program is SL-325, a DR3 antagonist antibody targeting the DR3/TL1A pathway.

The information is based on a company press release statement.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
• Breeze Acquisition Corp. II gets Nasdaq notice for late 10-Q filings